SCLX
NASDAQScilex Holding Company
Price$8.63-0.08 (-0.86%)
04:15 PM06:45 PM
News · 26 weeks43+33%
2026-01-182026-07-12
Mix2890d
- SEC Filings12(43%)
- Other6(21%)
- Dividends5(18%)
- Insider4(14%)
- Leadership1(4%)
Latest news
25 items- INSIDERLarge owner Sclx Stock Acquisition Jv Llc disposed of 500,000 shares, decreasing direct ownership by 34% to 958,263 units (SEC Form 4)4 - Scilex Holding Co (0001820190) (Issuer)
- PRScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Dream Bowl I Meme Coin tokens ("Dream Bowl Tokens") commence trading on the Biconomy Exchange on July 6, 2026. To view the Dream Bowl Tokens now trading on the Biconomy Exchange, please click https://www.biconomy.com/exchange/DREAM1_USDT. Scilex believes that the ability to trade the Dream Bowl Tokens may deliver liquidity
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPPALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced the signing of a binding term sheet with iHolding Group LLP ("iHolding"), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates that iHolding will purchase $100,000,000 of newly issued shares of Scilex common stock. The purchase price for such shares is expected to be $15.00 per share,
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Scilex Holding Co (0001820190) (Filer)
- INSIDERLarge owner Scilex Holding Co disposed of 7,034,737 shares (SEC Form 4)4 - Scilex Holding Co (0001820190) (Reporting)
- PROramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetSignificant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
- SECScilex Holding Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026PALO ALTO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced Dream Bowl I Meme Coin tokens ("Dream Bowl Tokens") to list on Biconomy Exchange as early as June 23, 2026. Scilex believes that such listing may deliver liquidity and allow for broad distribution of such tokens for the Participating Holders (as defined below). Biconomy serves more than 10 million users and institutions across 180+ co
- PRScilex Holding Company ("Scilex") Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesPALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today confirmed the previously announced payment date of June 15, 2026 (the "Payment Date") for the dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participating Holders") that held such securities as of the r
- SECSEC Form EFFECT filed by Scilex Holding CompanyEFFECT - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesPALO ALTO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") has set June 15, 2026 as the payment date (the "Payment Date") for the previously announced dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participati
- SECSEC Form S-3 filed by Scilex Holding CompanyS-3 - Scilex Holding Co (0001820190) (Filer)
- SECSEC Form EFFECT filed by Scilex Holding CompanyEFFECT - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026PALO ALTO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") approved a dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible equityholders of Scilex (collectively, the "Participating Holders"). The record date for the dividend is June 1, 2026 (the "Record Date"). Th
- SECSEC Form 10-Q filed by Scilex Holding Company10-Q - Scilex Holding Co (0001820190) (Filer)
- SECSEC Form NT 10-Q filed by Scilex Holding CompanyNT 10-Q - Scilex Holding Co (0001820190) (Filer)
- SECScilex Holding Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- SECSEC Form DEFA14A filed by Scilex Holding CompanyDEFA14A - Scilex Holding Co (0001820190) (Filer)
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings LimitedPALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its indirect subsidiary, ACEA Therapeutics, Inc, an exempted company incorporated with limited liability in the Cayman Islands ("ACEA Thera"), ACEA Pharma, Inc., an exempted company incorporated with limited liability in the Cayman Islands and wholly owned subsidiary of ACEA Thera ("ACEA Pharma"), and Phoenix Asia Holdings Limited,
- PRScilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") fixed May 26, 2026 (the "Payment Date") as the date on which the previously announced dividend (the "Dividend") of Dream Bowl Meme Coin I tokens held by the Company (the "Dream Bowl Tokens") will be paid to its record stockholders and certain other eligible equityholders of Scilex (collectively,
- SECSEC Form DEF 14A filed by Scilex Holding CompanyDEF 14A - Scilex Holding Co (0001820190) (Filer)
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Scilex Holding Co (0001820190) (Filer)
- PRDatavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum PlatformCombined with the anticipated sale of the BTC and Receivable collections, Datavault AI projects $200M+ infusion of cash without equity dilution. Datavault AI has previously secured and in stock of Nvidia GPUs that have a current market value of $1.2 billion that will enable the nationwide roll out. Datavault AI and Scilex have entered into a binding term sheet for a $120 million cash contribution from Scilex, in exchange for the right of Scilex to receive a portion of certain revenues recognized by Datavault AI attributable exclusively to its quantum-ready GPU infrastructure across an estimated 100 cities in the United States (the "Quantum-Ready Edge Network") with the aggregate annu
SCLX FAQ
6 questionsWhere does SCLX stock trade?
Scilex Holding Company (SCLX) is listed on NASDAQ.What sector and industry is SCLX in?
Scilex Holding Company operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Scilex Holding Company go public?
Scilex Holding Company (SCLX) completed its IPO in 2021.What are analysts saying about SCLX?
Scilex Holding Company has had 6 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $2200.00 price target on 2025-01-27.What companies are similar to SCLX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SCLX side-by-side with any of them on Quantisnow.How can I track SCLX on Quantisnow?
Quantisnow aggregates Scilex Holding Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SCLX to receive live email and push alerts on every new disclosure.